on Jaguar Health, Inc. (NASDAQ:JAGX)
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
Jaguar Health, Inc. (NASDAQ:JAGX) has announced that it regained compliance with Nasdaq's minimum bid price requirement as of June 25, 2024. The company’s securities will continue to be listed and traded on the Nasdaq stock exchange.
The company aims to report results from its pivotal phase 3 OnTarget trial for its cancer supportive care drug crofelemer by July 23, 2024. This development marks a significant milestone for Jaguar Health's ongoing efforts in the pharmaceutical field.
Jaguar Health's president and CEO, Lisa Conte, expressed satisfaction with the compliance news, emphasizing the value of their Nasdaq listing. An investor webcast is scheduled for on or before July 23, 2024, during which updates on the cancer supportive care portfolio will be discussed.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Jaguar Health, Inc. news